The use of prednisolone during Ramadan fasting in patients with adrenal insufficiency
ObjectiveOnce daily prednisolone taken at predawn has been proposed to be the glucocorticoid replacement of choice in patients with adrenal insufficiency (AI) who intend to fast for the month of Ramadan. However, the effects of prednisolone on metabolic parameters and quality of life during fasting...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Published: |
Wiley
2024
|
| Subjects: | |
| Online Access: | http://eprints.um.edu.my/45961/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | ObjectiveOnce daily prednisolone taken at predawn has been proposed to be the glucocorticoid replacement of choice in patients with adrenal insufficiency (AI) who intend to fast for the month of Ramadan. However, the effects of prednisolone on metabolic parameters and quality of life during fasting for Ramadan are unknown.Design, Patients and MeasurementsPatients with AI on twice-daily hydrocortisone, who had low or moderate risk and intended to fast, were recruited. Patients were converted to prednisolone 5 mg once daily taken at sahur (predawn) and Ramadan education given. Weight, sleep duration, biochemical parameters and quality of life measures (SF-36 questionnaire) were analysed at the end of Ramadan and compared against baseline.ResultsTwenty patients (13 men) were recruited, with a mean age of 59.9 +/- 15.0 years. All patients were on hydrocortisone 15 mg daily (in divided doses) as pre-Ramadan glucocorticoid replacement. Half had type 2 diabetes with low IDF-DAR risk. Eighty-five percent of patients completed the full 29 days of fasting with no complications. There was a significant reduction in weight (-1.1 +/- 1.6 kg, p = .005), with no significant change in blood pressure or sleep duration. There was a significant increase in urea (0.80 +/- 1.1 mmol/L, p = .005) and haematocrit, (0.011 +/- 0.019 L/L, p = .019) and decrease in serum sodium (-1.6 +/- 3.0 mmol/L, p = .028), with no change in serum creatinine or liver function. Quality of life measures were preserved in all domains with significant improvement in role limitation due to physical health (15.3 +/- 21.6, p = .005) and bodily pain (8.8 +/- 16.3, p = .031).ConclusionsThis study has demonstrated that converting patients with AI who are fasting for Ramadan from twice-daily hydrocortisone to prednisolone 5 mg daily at sahur was safe, with no major short-term adverse effects. Despite the higher equivalent glucocorticoid doses, patients experienced weight loss and no clinically significant change in blood pressure, sleep, biochemical parameters or quality of life. This study paves the way to trial even lower doses of prednisolone once daily in patients fasting for Ramadan with AI. |
|---|